Release Date: 23/01/14 09:29 Summary: Fourth Supplementary Bidder's Statement Price Sensitive: Yes Download Document 310.77KB Download
MSB Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%